

EMERGING ANTIMICROBIALS AND DIAGNOSTICS IN AMR 2019



INTERNATIONAL MATCHMAKING SYMPOSIUM
13 NOVEMBER 2019 • THE NETHERLANDS

ANTIMICROBIAL RESISTANCE (AMR)

Antimicrobial resistance (AMR) is considered the biggest global threat of Health and Food Safety (Source: WHO). AMR develops when bacteria, fungi, or viruses are exposed to antibiotics, antifungals or antivirals. As a result, the antimicrobials become ineffective and infections may persist. In addition, medical interventions including surgery, caesarian sections, chemotherapy and stem cell therapy may become impossible. It is estimated that AMR causes at least 700,000 casualties per year with the low- and middle income countries (LMIC) bearing the harshest burdens. More recent recalculations indicate substantially higher numbers. According to the 'Review on Antimicrobial Resistance' by Jim O'Neill we may face some 10,000,000 casualties per year in 2050 with cumulative GDP loss of \$ 100 trillionⁱⁱ. "Planet earth faces the very real threat of having to survive in a 'post-antibiotic' era in which there are few, if any, antibiotics which effectively and affordably cure infections".ⁱⁱⁱ

Both at an international as well as at a national level action plans have been set up to fight AMR. These plans have five 'strategies' in common:

1. Better prevention of infectious diseases
2. Further implementing antibiotics stewardship
3. Developing improved microbiological diagnostics
4. Developing new (classes of) antibiotics
5. Developing alternative antimicrobial strategies (like phage therapy).

The event focuses on the strategies 3, 4 and 5.

SYMPOSIUM SUMMARY

EMERGING ANTIMICROBIALS AND DIAGNOSTICS IN AMR 2019

The aim of the event is to identify, highlight and enhance the further development and marketing of new and promising molecules, antimicrobial strategies and their platform technologies as well as novel diagnostics and technologies. Applicable sectors include the human and veterinary health care, innovative food and dairy industries and the environmental & water sectors. The event is a one day matchmaking symposium on 13 November, 2019 in The Netherlands.

Target groups include international:

- **Academia:** (professional) universities, medical centers and research institutions
- **Private sector:** start-up's, SME's, multinational Pharma, Diagnostics & Life Sciences
- **Public institutions:** hospitals, diagnostics labs, CRO's
- **Finance:** business angels, financiers, (social impact) venture capitalists
- **Others:** patent offices, insurance companies

Visit the preliminary website and read more on the anticipated program:

<https://www.amr-insights.eu/emerging-antimicrobials-and-diagnostics-in-amr-2019/>

ⁱ <https://www.who.int/en/news-room/fact-sheets/detail/antimicrobial-resistance>

ⁱⁱ <https://amr-review.org/>

ⁱⁱⁱ <https://www.daghammarskjold.se/publication/antimicrobial-resistance-and-sustainable-development-a-planetary-threat-but-a-financing-orphan/>